A Clinical and Pharmacokinetic Study of the Effectiveness of Hepatitis C Treatment (Sofosbuvir+Daclatasvir) in HIV Co-infected and Non HIV Co-infected Patients at the Level of Non-hospital Based Management in Myanmar
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 Aug 2017 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.
- 30 Aug 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
- 30 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Nov 2017.